Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 19/20 | 0.72 |
| ▸ | JAK2 | O60674 | 2/20 | 0.57 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4043572 | 0.84 | PTGES (0.79) | PTGESJAK2 | |
| SCHEMBL4354984 | 0.76 | PTGES (0.92) | PTGESJAK2JAK3 | |
| SCHEMBL4049140 | 0.76 | PTGES (0.91) | PTGESJAK2JAK3 | |
| SCHEMBL4352518 | 0.73 | PTGES (0.77) | PTGESJAK2 | |
| SCHEMBL4370308 | 0.73 | PTGES (0.62) | PTGESJAK2JAK3CYP2C9 | |
| SCHEMBL14433682 | 0.72 | PTGES (0.64) | PTGESJAK2JAK3 | |
| SCHEMBL1758282 | 0.71 | PTGES (1.00) | PTGESJAK2JAK3 | |
| SCHEMBL4050656 | 0.71 | PTGES (0.71) | PTGESJAK2CYP2C9 | |
| SCHEMBL4361691 | 0.70 | PTGES (1.00) | PTGESJAK2JAK3 | |
| SCHEMBL12329985 | 0.70 | PTGES (0.80) | PTGESJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286772-A1 | 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles | MERCK & CO., INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286772-A1 | 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles | MERCK & CO., INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286772-A1 | 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles | MERCK & CO., INC. | 2009-11-19 | — | — | US | disclosed |
| WO-2007095753-A1 | 2-(PHENYL OR HETEROCYCLIC) - 1H-PHENANTHRO [9,10-D] IMIDAZOLES | MERCK FROSST CANADA LTD. (CA) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286772-A1 | 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles | PTGES, PTGS1, PTGES2 | PTGES 1/4885JAK2 1520/4885JAK3 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.